Abdominal Pain
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Boehringer IngelheimINGELHEIM, Germany
1 program1
Hyoscine Butylbromide - TabletPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Boehringer IngelheimHyoscine Butylbromide - Tablet
CENTOGENEEpidemiological Analysis for Hereditary Angioedema Disease
Clinical Trials (2)
Total enrollment: 2,620 patients across 2 trials
Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort
Start: Nov 2008Est. completion: Jul 2009302 patients
Phase 3Completed
Epidemiological Analysis for Hereditary Angioedema Disease
Start: Sep 2018Est. completion: Apr 20222,318 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space